Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

48.13 -0.24 (-0.50%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
40 41 Next >
News headline image
Why NASDAQ:SNY qualifies as a good dividend investing stock. ↗
Balancing Dividends and Fundamentals: The Case of SANOFI-ADR (NASDAQ:SNY). 
Via Chartmill
News headline image
Kennedy's Lawyer Urges FDA To Revoke Polio Vaccine Approval, Endangering Millions Of Children ↗
Lawyer files petition against polio vaccine, part of broader anti-vaccine campaign by Robert F. Kennedy Jr. and Aaron Siri, causing concerns for vaccine policies and pharma companies. Trump considering... 
Via Benzinga
Topics Government
News headline image
2 Beaten-Down "Pandemic Stocks" to Consider for Contrarian Investors ↗
Via The Motley Fool
News headline image
Jim Cramer: This Energy Stock Is A 'Winner,' But Navitas Semiconductor Is 'Losing A Lot Of Money' ↗
Navitas Semiconductor is losing money according to Jim Cramer. LandBridge Company is a winner, while Regeneron is facing sales challenges. 
Via Benzinga
News headline image
NVIDIA Invested in These 2 AI Stocks, Should You?
Discover 2 compelling AI stocks NVIDIA (NASDAQ: NVDA) has invested in. Learn how the AI leader's vision can guide your portfolio in the tech revolution. 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Balancing Dividends and Fundamentals: The Case of NASDAQ:SNY. ↗
Is SANOFI-ADR (NASDAQ:SNY) suited for dividend investing? 
Via Chartmill
News headline image
Sanofi's Earnings Outlook ↗
 
Via Benzinga
News headline image
NASDAQ:SNY is probably undervalued for the fundamentals it is displaying. ↗
SANOFI-ADR (NASDAQ:SNY) stands out as a stock that provides good value for the fundamentals it showcases. 
Via Chartmill
News headline image
Bird Flu Found In Raw Milk Leads To Recall In California ↗
Bird flu has been detected in a batch of raw milk sold in California and a voluntary recall of the milk has been issued at the request of the state's department of public health. 
Via Benzinga
Topics Product Recall
News headline image
Big Pharma's Pharmacy-Benefit Managers Accuse FTC of Overreach In Effort to Reshape Drug Rebate System ↗
PBMs Express Scripts, Caremark, and Optum challenge the FTC's administrative proceedings, arguing it violates constitutional rights and threatens the stability of drug pricing. 
Via Benzinga
News headline image
Mutated Bird Flu Case In California Puts Humans At Increased Risk, So Which Companies Are Developing Vaccines? ↗
According to the Los Angeles Times, the total bird flue case count in the U.S. stands at 54; 31 cases are attributed to the dairy industry. 
Via Benzinga
News headline image
European And US Vaccine Stocks Are Under Pressure - Here's WHy ↗
Vaccine stocks react to Robert F. Kennedy Jr.'s HHS nomination. FDA and NIH express concerns over his anti-vaccine views amid market shifts. 
Via Benzinga
News headline image
FDA To Revisit Regeneron/Sanofi's Dupixent For Rare Skin Disease ↗
Regeneron and Sanofi's Dupixent sBLA for treating chronic spontaneous urticaria in patients 12+ gets FDA review, with a decision expected by April 2025. 
Via Benzinga
News headline image
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Viking Fund Management Sells Big Oil Stocks In Q3, Cuts Tesla Position In Half, Adds To Largest Position Broadcom ↗
A look at the moves made by Viking Fund management in the third quarter, including the exits and new stakes and fund's largest positions at the end of Q3. 
Via Benzinga
News headline image
Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease ↗
After years of limited advancements in chronic obstructive pulmonary disease (COPD) treatment, patients now have new options. 
Via Benzinga
News headline image
Humanitarian Organization Criticizes Eli Lilly, Novo Nordisk And Sanofi Of Having 'Double Standards' For High Insulin Price ↗
MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access. Novo Nordisk's production shift raises concerns as diabetes cases rise,... 
Via Benzinga
News headline image
Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks ↗
The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers Squibb, Gilead Sciences, and Sanofi, despite challenges for Novo Nordisk and... 
Via Benzinga
News headline image
NASDAQ:SNY stands out as a stock that provides good value for the fundamentals it showcases. ↗
SANOFI-ADR (NASDAQ:SNY) is probably undervalued for the fundamentals it is displaying. 
Via Chartmill
News headline image
Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say ↗
Upstream Bio garners analyst optimism for its lead drug verekitug, which could disrupt the $7.5 billion asthma biologics market. 
Via Benzinga
News headline image
FDA Panel Rejects Lexicon's Zynquista For Type 1 Diabetes ↗
Lexicon Pharmaceuticals' sotagliflozin, under review as an adjunct to insulin for type 1 diabetes and CKD, faced an FDA panel vote against approval, with mixed expert support. 
Via Benzinga
News headline image
Why Is Regeneron Pharmaceuticals Stock Trading Lower Today? ↗
Regeneron reports Q3 EPS of $12.46, up 8% YoY, beating estimates. Revenue rose 11% to $3.72 billion. Key growth from Eylea, Libtayo, and Dupixent drives performance. 
Via Benzinga
News headline image
Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split ↗
One of these players has split its stock in the past. The other one hasn't. 
Via The Motley Fool
News headline image
Why Sanofi Stock Flew Higher on Friday ↗
No investor can ignore a crushing bottom-line beat and raised profitability guidance. 
Via The Motley Fool
News headline image
Sanofi (SNY) Q3 2024 Earnings Call Transcript ↗
SNY earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
Eli Lilly's Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron's Dupixent ↗
Eli Lilly's Ebglyss improves skin and itch symptoms in eczema patients, including Dupixent-treated cases, with positive Phase 3b ADapt study results shared. 
Via Benzinga
News headline image
Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat ↗
The company also hiked its profit outlook for the year and expects single-digit growth. 
Via Investor's Business Daily
News headline image
Sanofi Earns $5B Q3 Core Profit On Strong Dupixent And Vaccine Sales, Raises 2024 Forecast ↗
Sanofi's Q3 earnings surged, with a 14.4% increase in income to €4.61 billion, led by Dupixent and new launches. Revenue beat estimates, reaching €13.44 billion, up 12.3%. 
Via Benzinga
News headline image
Markets Mixed Again; DECK, SKX Beat After The Bell ↗
Over the past week or so of trading, we’ve seen the stock market begin to snarl at current valuation levels. 
Via Talk Markets
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
40 41 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.